Line 9: | Line 9: | ||
<h1 class="headline">CATE in Action</h1> | <h1 class="headline">CATE in Action</h1> | ||
− | + | <section> | |
− | + | ||
<p>We decided to work with the probiotic <i>E. coli</i> Nissle 1917, due to its inherent tumor targeting capabilities and lack of pathogenicity, which make it the ideal chassis for development of precisely controllable features that we decided to integrate into the therapeutic. <a href="#bib1" class="forward-ref">[1]</a><a href="#bib2" class="forward-ref">[2]</a></p> | <p>We decided to work with the probiotic <i>E. coli</i> Nissle 1917, due to its inherent tumor targeting capabilities and lack of pathogenicity, which make it the ideal chassis for development of precisely controllable features that we decided to integrate into the therapeutic. <a href="#bib1" class="forward-ref">[1]</a><a href="#bib2" class="forward-ref">[2]</a></p> |
Revision as of 08:19, 31 October 2017
CATE in Action
We decided to work with the probiotic E. coli Nissle 1917, due to its inherent tumor targeting capabilities and lack of pathogenicity, which make it the ideal chassis for development of precisely controllable features that we decided to integrate into the therapeutic. [1][2]
We envision the treatment to follow the strategy described below. A short duration, enhanced safety and overall effectiveness are expected to be decisive factors for choosing to treat with CATE instead of conventional therapies.
The procedure revolves around two safety Checkpoints, unique to our design. Checkpoint 1 is an internal checkpoint where the bacteria identify the tumor and decide if they can proceed with the treatment, while Checkpoint 2 represent and external checkpoint manipulated by the physician. With the combination of the two, we believe to have designed a system of superior security.
The following steps will guide you through the treatment. To find out more about how each of the described steps works, click on the links below that will guide you to a detailed description of each function implemented in CATE.
References
- Forbes, Neil S. "Engineering the perfect (bacterial) cancer therapy." Nature reviews. Cancer 10.11 (2010): 785. doi: 10.1038/nrc2934
- Stritzker, Jochen, et al. "Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice." International journal of medical microbiology 297.3 (2007): 151-162. doi: 10.1016/j.ijmm.2007.01.008
- Hirschhaeuser, Franziska, Ulrike GA Sattler, and Wolfgang Mueller-Klieser. "Lactate: a metabolic key player in cancer." Cancer research 71.22 (2011): 6921-6925. doi: 10.1158/0008-5472.CAN-11-1457
- Ebbini, Emad S., and Gail Ter Haar. "Ultrasound-guided therapeutic focused ultrasound: current status and future directions." International Journal of Hyperthermia 31.2 (2015): 77-89. doi: 10.3109/02656736.2014.995238
- Yamada, Tohru, et al. "Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer." Proceedings of the National Academy of Sciences 99.22 (2002): 14098-14103. doi: 10.1073/pnas.222539699
- Bernardes, Nuno, et al. "Modulation of membrane properties of lung cancer cells by azurin enhances the sensitivity to EGFR-targeted therapy and decreased β1 integrin-mediated adhesion." Cell Cycle 15.11 (2016): 1415-1424. doi: 10.1080/15384101.2016.1172147